Neurodegenerative disease company Transquis has emerged from stealth with $30m in series A funding to advance research conducted at Stanford.

Eir’s first fund will partner Nordics-based universities to invest in their spinouts, while also making selected deals in the rest of Europe and the US.

Novo is among the limited partners for Eir Ventures, which has launched with $86m to invest in life sciences technology startups.

Eli Lilly and Horizon Therapeutics contributed to the life sciences venture firm's Forbion Growth Opportunities Fund, which will make late-stage investments.

NFP and Alphabet's GV unit contributed to a series B round that will help the fertility and gynaecology services startup expand its brick-and-mortar outlets.

The neurodegenerative disease startup has emerged from stealth with $30m taken in a series A round co-led by GlaxoSmithKline's SR One unit.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The Zhejiang University Future Capital-backed cancer and inflammatory disease drug developer has now raised more than $260m in under two years.

The SK Holdings, China Life and Legend Holdings-backed cancer and inflammatory disease drug developer has now raised more than $260m in under two years.

University of Birmingham‘s infectious disease reagent producer Native Antigen Company has been acquired in a deal enabling Mercia Asset Management to exit.